Vanguard Group Inc Maxcyte, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,429,681 shares of MXCT stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,429,681
Previous 5,775,268
5.98%
Holding current value
$16.8 Million
Previous $22.5 Million
0.54%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding MXCT
# of Institutions
123Shares Held
69.8MCall Options Held
8.7KPut Options Held
6K-
Cadian Capital Management, LP New York, NY9.34MShares$28.9 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$25.2 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$15.6 Million18.06% of portfolio
-
Morgan Stanley New York, NY4.41MShares$13.6 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X03.7MShares$11.4 Million1.48% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $314M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...